Tofacitinib
Indication
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA543)
MHRA Drug Safety Update, 6 October 2021
Major Adverse Cardiovascular Events MHRA Drug Safety Update
Brand:
Xeljanz
Nice TA:
543
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:
• it is used as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
• TNF alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Tofacitinib is only recommended if the company provides it according to the commercial arrangement.